Erratum to: MYC-driven epigenetic reprogramming favors the onset of tumorigenesis by inducing a stem cell-like state (Nature Communications, (2018), 9, 1, (1024), 10.1038/s41467-018-03264-2);MYC-driven epigenetic reprogramming favors the onset of tumorigenesis by inducing a stem cell-like state

Nature Communications

Volumn 9, Issue 1, 2018, Pages

  Poli, Vittoria ^a,b   Fagnocchi, Luca ^a,b,c   Fasciani, Alessandra ^a,b   Cherubini, Alessandro ^b   Mazzoleni, Stefania ^b   Ferrillo, Sara ^b   Miluzio, Annarita ^b   Gaudioso, Gabriella ^b,d   Vaira, Valentina ^b,d   Turdo, Alice ^e   Giaggianesi, Miriam ^e   Chinnici, Aurora ^e   Lipari, Elisa ^e   Bicciato, Silvio ^f   Bosari, Silvano ^d   Todaro, Matilde ^e   Zippo, Alessio ^a,b,c  

^a UNIVERSITY OF TRENTO   (Italy)

^b Istituto Nazionale di Genetica Molecolare   (Italy)

^c FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e UNIVERSITY OF PALERMO   (Italy)

^f UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CADHERIN; CYTOKINE; EPIDERMAL GROWTH FACTOR RECEPTOR; HISTONE; INTEGRIN; MYC PROTEIN; PLASMINOGEN; PLATELET DERIVED GROWTH FACTOR; STAT1 PROTEIN; STAT3 PROTEIN; STAT5A PROTEIN; STAT5B PROTEIN; TRANSCRIPTION FACTOR GATA 3;

CANCER; CELL; GENE EXPRESSION; RNA; TUMOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BASAL LIKE BREAST CANCER; BREAST CANCER; BREAST CARCINOGENESIS; BREAST EPITHELIUM CELL; CELL ACTIVATION; CELL DEDIFFERENTIATION; CELL PLASTICITY; CONTROLLED STUDY; EMBRYO; EPIGENETIC REPRESSION; EPIGENETICS; EXTRACELLULAR MATRIX; GENE EXPRESSION PROFILING; GENE ONTOLOGY; GENE OVEREXPRESSION; GENOMIC INSTABILITY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUCLEAR REPROGRAMMING; PROMOTER REGION; SIGNAL TRANSDUCTION; STEM CELL; STEM CELL SELF-RENEWAL; TGF BETA SIGNALING; TRANSCRIPTION INITIATION; TUMOR VOLUME; WNT SIGNALING; ANIMAL; BREAST TUMOR; CANCER STEM CELL; CARCINOGENESIS; CYTOLOGY; ENHANCER REGION; FEMALE; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; METABOLISM; PATHOPHYSIOLOGY; SCID MOUSE; TUMOR CELL LINE;

ANIMALS; BREAST NEOPLASMS; CARCINOGENESIS; CELL LINE, TUMOR; CELLULAR REPROGRAMMING; ENHANCER ELEMENTS, GENETIC; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, SCID; NEOPLASTIC STEM CELLS; PROTO-ONCOGENE PROTEINS C-MYC;

EID: 85044003494     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/s41467-018-06480-y     Document Type: Erratum

References (70)

1. Hanahan, D. &Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646-674 (2011).
2. Feinberg, A. P. &Tycko, B. The history of cancer epigenetics. Nat. Rev. Cancer 4, 143-153 (2004).
3. Visvader, J. E. &Lindeman, G. J. Cancer stem cells: current status and evolving complexities. Cell Stem Cell 10, 717-728 (2012).
4. Barker, N. et al. Crypt stem cells as the cells-of-origin of intestinal cancer. Nature 457, 608-611 (2009).
5. Chaffer, C. L. et al. Poised chromatin at the ZEB1 promoter enables breast cancer cell plasticity and enhances tumorigenicity. Cell 154, 61-74 (2013).
6. Schwitalla, S. et al. Intestinal tumorigenesis initiated by dedifferentiation and acquisition of stem-cell-like properties. Cell 152, 25-38 (2013).
7. Friedmann-Morvinski, D. et al. Dedifferentiation of neurons and astrocytes by oncogenes can induce gliomas in mice. Science 338, 1080-1084 (2012).
8. Molyneux, G. et al. BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. Cell Stem Cell 7, 403-417 (2010).
9. Lim, E. et al. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat. Med. 15, 907-913 (2009).
10. Van Keymeulen, A. et al. Reactivation of multipotency by oncogenic PIK3CA induces breast tumour heterogeneity. Nature 525, 119-123 (2015).
11. Koren, S. et al. PIK3CA(H1047R) induces multipotency and multi-lineage mammary tumours. Nature 525, 114-118 (2015).
12. Apostolou, E. &Hochedlinger, K. Chromatin dynamics during cellular reprogramming. Nature 502, 462-471 (2013).
13. Feinberg, A. P., Koldobskiy, M. A. &Gondor, A. Epigenetic modulators, modifiers and mediators in cancer aetiology and progression. Nat. Rev. Genet. 17, 284-299 (2016).
14. Fagnocchi, L., Mazzoleni, S. &Zippo, A. Integration of Signaling Pathways with the Epigenetic Machinery in the Maintenance of Stem Cells. Stem Cells Int. 2016, 8652748 (2016).
15. Calo, E. &Wysocka, J. Modification of enhancer chromatin: what, how, and why? Mol. Cell 49, 825-837 (2013).
16. Heinz, S., Romanoski, C. E., Benner, C. &Glass, C. K. The selection and function of cell type-specific enhancers. Nat. Rev. Mol. Cell Biol. 16, 144-154 (2015).
17. Whyte, W. A. et al. Enhancer decommissioning by LSD1 during embryonic stem cell differentiation. Nature 482, 221-225 (2012).
18. Kaufman, C. K. et al. A zebrafish melanoma model reveals emergence of neural crest identity during melanoma initiation. Science 351, aad2197 (2016).
19. Shen, H. et al. Suppression of enhancer overactivation by a RACK7-histone demethylase complex. Cell 165, 331-342 (2016).
20. Hnisz, D. et al. Super-enhancers in the control of cell identity and disease. Cell 155, 934-947 (2013).
21. Vogelstein, B. et al. Cancer genome landscapes. Science 339, 1546-1558 (2013).
22. Herz, H. M., Hu, D. &Shilatifard, A. Enhancer malfunction in cancer. Mol. Cell 53, 859-866 (2014).
23. Takahashi, K. &Yamanaka, S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126, 663-676 (2006).
24. Dang, C. V. MYC on the path to cancer. Cell 149, 22-35 (2012).
25. Cancer Genome Atlas, N. Comprehensive molecular portraits of human breast tumours. Nature 490, 61-70 (2012).
26. Chandriani, S. et al. A core MYC gene expression signature is prominent in basal-like breast cancer but only partially overlaps the core serum response. PLoS ONE 4, e6693 (2009).
27. Fagnocchi, L. et al. A Myc-driven self-reinforcing regulatory network maintains mouse embryonic stem cell identity. Nat. Commun. 7, 11903 (2016).
28. Fagnocchi, L. &Zippo, A. Multiple roles of MYC in integrating regulatory networks of pluripotent stem cells. Front. Cell Dev. Biol. 5, 7 (2017).
29. Lin, C. Y. et al. Transcriptional amplification in tumor cells with elevated c-Myc. Cell 151, 56-67 (2012).
30. Sabo, A. et al. Selective transcriptional regulation by Myc in cellular growth control and lymphomagenesis. Nature 511, 488-492 (2014).
31. Liu, Z. et al. Enhancer activation requires trans-recruitment of a mega transcription factor complex. Cell 159, 358-373 (2014).
32. Theodorou, V., Stark, R., Menon, S. &Carroll, J. S. GATA3 acts upstream of FOXA1 in mediating ESR1 binding by shaping enhancer accessibility. Genome Res. 23, 12-22 (2013).
33. Shin, H. Y. et al. Hierarchy within the mammary STAT5-driven Wap superenhancer. Nat. Genet. 48, 904-911 (2016).
34. Frietze, S. et al. Global analysis of ZNF217 chromatin occupancy in the breast cancer cell genome reveals an association with ERalpha. Bmc Genom. 15, 520 (2014).
35. Asselin-Labat, M. L. et al. Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation. Nat. Cell Biol. 9, 201-209 (2007).
36. Kouros-Mehr, H., Slorach, E. M., Sternlicht, M. D. &Werb, Z. GATA-3 maintains the differentiation of the luminal cell fate in the mammary gland. Cell 127, 1041-1055 (2006).
37. Walz, S. et al. Activation and repression by oncogenic MYC shape tumourspecific gene expression profiles. Nature 511, 483-487 (2014).
38. Wiese, K. E. et al. Repression of SRF target genes is critical for Myc-dependent apoptosis of epithelial cells. Embo J. 34, 1554-1571 (2015).
39. Curtis, C. et al. The genomic and transcriptomic architecture of 2000 breast tumours reveals novel subgroups. Nature 486, 346-352 (2012).
40. Mertins, P. et al. Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 (2016).
41. Dontu, G., Al-Hajj, M., Abdallah, W. M., Clarke, M. F. &Wicha, M. S. Stem cells in normal breast development and breast cancer. Cell Prolif. 36, 59-72 (2003).
42. Charafe-Jauffret, E. et al. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res. 69, 1302-1313 (2009).
43. Reya, T. &Clevers, H. Wnt signalling in stem cells and cancer. Nature 434, 843-850 (2005).
44. Barry, E. R. et al. Restriction of intestinal stem cell expansion and the regenerative response by YAP. Nature 493, 106-110 (2013).
45. Kim, J. et al. A Myc network accounts for similarities between embryonic stem and cancer cell transcription programs. Cell 143, 313-324 (2010).
46. Nie, Z. et al. c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells. Cell 151, 68-79 (2012).
47. Jin, F. et al. A high-resolution map of the three-dimensional chromatin interactome in human cells. Nature 503, 290-294 (2013).
48. Adam, R. C. et al. Pioneer factors govern super-enhancer dynamics in stem cell plasticity and lineage choice. Nature 521, 366-370 (2015).
49. Cordenonsi, M. et al. The Hippo transducer TAZ confers cancer stem cellrelated traits on breast cancer cells. Cell 147, 759-772 (2011).
50. Vermeulen, L. et al. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat. Cell Biol. 12, 468-476 (2010).
51. Todaro, M. et al. CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis. Cell Stem Cell 14, 342-356 (2014).
52. Larsimont, J. C. et al. Sox9 controls self-renewal of oncogene targeted cells and links tumor initiation and invasion. Cell Stem Cell 17, 60-73 (2015).
53. Khramtsov, A. I. et al. Wnt/beta-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome. Am. J. Pathol. 176, 2911-2920 (2010).
54. Guo, W. et al. Slug and Sox9 cooperatively determine the mammary stem cell state. Cell 148, 1015-1028 (2012).
55. Parker, S. C. et al. Chromatin stretch enhancer states drive cell-specific gene regulation and harbor human disease risk variants. Proc. Natl. Acad. Sci. USA 110, 17921-17926 (2013).
56. Merlos-Suarez, A. et al. The intestinal stem cell signature identifies colorectal cancer stem cells and predicts disease relapse. Cell Stem Cell 8, 511-524 (2011).
57. Friedmann-Morvinski, D. &Verma, I. M. Dedifferentiation and reprogramming: origins of cancer stem cells. Embo Rep. 15, 244-253 (2014).
58. Eirew, P. et al. A method for quantifying normal human mammary epithelial stem cells with in vivo regenerative ability. Nat. Med. 14, 1384-1389 (2008).
59. Parmar, H. et al. A novel method for growing human breast epithelium in vivo using mouse and human mammary fibroblasts. Endocrinology 143, 4886-4896 (2002).
60. Opitz, C. A. et al. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature 478, 197-203 (2011).
61. Wang, D. &Dubois, R. N. Eicosanoids and cancer. Nat. Rev. Cancer 10, 181-193 (2010).
62. Anastas, J. N. &Moon, R. T. WNT signalling pathways as therapeutic targets in cancer. Nat. Rev. Cancer 13, 11-26 (2013).
63. Gabay, M., Li, Y. &Felsher, D. W. MYC activation is a hallmark of cancer initiation and maintenance. Cold Spring Harb. Perspect. Med. 4, a014241 (2014).
64. Rahl, P. B. et al. c-Myc regulates transcriptional pause release. Cell 141, 432-445 (2010).
65. Wang, J. et al. FOXC1 regulates the functions of human basal-like breast cancer cells by activating NF-kappaB signaling. Oncogene 31, 4798-4802 (2012).
66. Ray, P. S. et al. FOXC1 is a potential prognostic biomarker with functional significance in basal-like breast cancer. Cancer Res. 70, 3870-3876 (2010).
67. Brooks, M. D., Burness, M. L. &Wicha, M. S. Therapeutic implications of cellular heterogeneity and plasticity in breast cancer. Cell Stem Cell 17, 260-271 (2015).
68. Enzo, E. et al. Aerobic glycolysis tunes YAP/TAZ transcriptional activity. Embo J. 34, 1349-1370 (2015).
69. Rustighi, A. et al. Prolyl-isomerase Pin1 controls normal and cancer stem cells of the breast. EMBO Mol. Med. 6, 99-119 (2014).
70. Adorno, M. et al. A mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell 137, 87-98 (2009).